Skye Bioscience, Inc. filed a Form 8-K on November 12, 2026, reporting that on November 10, 2026, a jury returned a unanimous verdict in favor of the company on all claims in the retrial of Wendy Cunning vs Skye Bioscience, Inc. in the U.S. District Court for the Central District of California.

Key Highlights

  • Unanimous verdict: The jury returned a unanimous verdict in favor of Skye Bioscience on all claims on November 10, 2026, following a retrial in the District Court.
  • Case background: Former employee Wendy Cunning alleged violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law, relating to events during her employment from March 2018 to July 2019.
  • Damages sought: The original complaint sought unspecified economic and non-economic losses, as well as attorneys' fees.
  • Judgment pending: The company stated it expects the District Court will enter judgment "in due course."
  • Appeal possible: According to the filing, the plaintiff may file post-trial motions and may appeal any judgment entered on the verdict.
  • Pending acquisition: The filing also references a proposed acquisition of Redx Pharma Limited by Skye Bioscience under a Transaction Agreement dated August 14, 2026.

Skye Bioscience Retrial Outcome and Litigation Status

According to the filing, the lawsuit - Wendy Cunning vs Skye Bioscience, Inc. - was previously disclosed in Skye's Quarterly Report on Form 10-Q filed on August 14, 2026. The case was brought in the U.S. District Court for the Central District of California. The former employee alleged whistleblower protection violations under the Sarbanes-Oxley Act of 2002 and retaliation under California law, with the alleged actions tied to the company's former management during her employment term from March 2018 to July 2019.

The filing states that on November 10, 2026, following the retrial, the jury returned a unanimous verdict in favor of the company on all claims. Skye Bioscience, Inc. (NASDAQ:SKYE) disclosed that it expects the District Court to enter judgment in due course, while noting that "the plaintiff may file post-trial motions and may appeal any judgment entered on the verdict." The company stated it "cannot predict whether the plaintiff will do so or the outcome of any such motion or appeal."

Separately, the filing includes disclosures related to Skye's proposed acquisition of Redx Pharma Limited. The company noted it has filed a preliminary proxy statement with the SEC in connection with that transaction and directed stockholders to review the proxy statement and related documents when available. The filing identifies a Transaction Agreement dated August 14, 2026, between Skye Bioscience and Redx. Forward-looking statements in the filing regarding the proposed transaction are identified as subject to the company's cautionary language and the risks described therein.

What Was Disclosed

Skye Bioscience reported a November 10, 2026, unanimous jury verdict in its favor on all claims in the retrial of a former employee's whistleblower and retaliation lawsuit, while noting that post-trial motions or an appeal remain possible and their outcomes cannot be predicted.